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Abstract 
 
Objectives:  
We evaluated whether African Americans (AA) with intermediate to high-risk prostate cancer 
receive similar treatment as white patients and whether any observed disparities are persistent 
with time, across age groups, or by insurance status. 
 
Methods:  
We used the Surveillance, Epidemiology, and End Results (SEER) database to identify 128,189 
men with localized intermediate to high-risk prostate cancer (PSA > 10 or Gleason > 7 or T stage 
> T2b) diagnosed from 2004 – 2010.  We used multivariable logistic regression analyses to 
determine the impact of race on the receipt of definitive treatment and Fine-Gray competing risks 
regression to determine the impact of race on cancer mortality. 
 
Results:  
After adjusting for treatment, demographics, and prognostic factors, AA men had a higher risk of 
prostate-cancer specific mortality (AHR 1.12; 95% CI 1.01 – 1.25; P = 0.03).  AA men were 
significantly less likely to receive curative-intent treatment than white men (Adjusted Odds Ratio 
[AOR] 0.82; 95% CI 0.79 – 0.86; P < 0.001).   There was no evidence of this disparity 
narrowing over time (Pinteraction 2010 vs. 2004 = 0.490).  Disparities in the receipt of treatment 
between AA and white men were significantly larger in high-risk (AOR 0.60; 95% CI 0.56 – 
0.64; P < 0.001) than in intermediate-risk disease (AOR 0.92; 95% CI 0.88 – 0.97; P = 0.04), 
(Pinteraction < 0.001). The adjusted odds of receiving definitive treatment for AA vs. white men 
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was 0.67 (95% CI 0.62 – 0.73; P <0.001) among men age <70, but was 0.60 (95% CI 0.55 – 
0.66; P <0.001) among men age >70, suggesting increased racial disparity in the receipt of 
definitive treatment among older men (Pinteraction = 0.01).  Among uninsured men, the adjusted 
OR for definitive treatment for AA vs. white was 0.38 (95% CI 0.27 – 0.54; P < 0.001), but 
among insured men, the adjusted OR was 0.62 (95% CI 0.57 – 0.66; P<0.001), (Pinteraction = 0.01). 
 
Conclusions:  
AA men with high-risk prostate cancer were significantly less likely to receive potentially life-
saving definitive treatment when compared to white men.  This disparity is worse in high-risk 
disease and among men age >70, and is not improving over time.  Having health insurance was 
associated with a reduction in this racial treatment disparity, suggesting that expansion of health 
insurance coverage may help reduce racial disparities in the management of aggressive prostate 
cancer.  Factors underlying these treatment disparities should be urgently studied, as they are 
potentially correctable contributors to excess prostate cancer mortality among AA patients.  
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Glossary of Abbreviations 
ACA- Affordable Care Act 
AHR- Adjusted Hazard Ratio 
AJCC 
AOR- Adjusted Odds Ratio 
CI- Confidence Interval 
HR- Hazard Ratio 
PCSM- Prostate Cancer Specific Mortality 
PSA- Prostate Specific Antigen 
NCCN- National Comprehensive Cancer Network 
OR- Odds Ratio 
SEER- Surveillance, Epidemiology, and End Results 
 
 
 
 
 
 
 
 
 
 
 
6 
 
Introduction 
Prostate cancer represents the most commonly diagnosed non-cutaneous malignancy in 
men and there will be approximately 238,590 new cases of prostate cancer and 29,480 deaths 
due to prostate cancer in the United States in 2014; nearly 1 in 6 men will be diagnosed with 
prostate cancer in their lifetime.[1, 2]  Risk stratification based on prostate-specific antigen 
(PSA), Gleason score, and clinical T-category predicts prostate cancer outcomes after treatment 
with curative intent for localized prostate cancer.[3-6]  For patients with intermediate to high-risk 
prostate cancer, definitive treatments have been shown to decrease PCSM and improve overall 
survival and well defined guidelines have been established by the National Comprehensive 
Cancer Network (NCCN) based on these results.[3, 7-12]   
African American men are more likely to be diagnosed with lethal forms of prostate 
cancer and are nearly twice as likely to die from prostate cancer when compared to white men.[1, 
13]  It is unknown how much of this is due to differences in biology versus disparities in 
treatment patterns and access to care.[14-17]  Despite these differences in disease outcome and 
the well-defined NCCN guidelines mentioned above, racial and socioeconomic disparities in the 
management of prostate cancer have previously been suggested, although most prior studies have 
not been able to adequately describe and elucidate treatment patterns and survival outcome based 
on sociodemographic factors (including race) due to limited registry details and short follow-up 
available at the time of the studies.[14, 18, 19]  
Prior large U.S. national cohort studies that examined racial disparities in prostate cancer 
used data from over a decade ago and were not able to assess racial differences in the 
management of prostate cancer by NCCN risk group given the lack of complete clinical 
information in the data sets used at the time of the studies.[14, 20]  There is a paucity of 
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literature that examines racial disparities in prostate cancer by NCCN risk groups and evidence is 
conflicting as to whether racial disparities in the use of definitive treatment change with more 
advanced disease.[14, 21, 22]   
Furthermore, most level 1-evidence for definitive therapy comes from studies focusing on 
men age < 65.[3, 4, 7, 8, 10-12, 23]  Hence, the role of age in the management of patients with 
prostate cancer has been controversial.[24, 25] Many urologists postulate that the upper age limit 
for radical prostatectomy should be 70, and men over the age of 70 have been shown to receive 
curative treatment significantly less often than younger men.[24-29]  Despite the challenges 
associated with managing older adults with prostate cancer, it has been suggested that definitive 
therapy results in significantly higher life expectancy as well as quality-adjusted life expectancy 
in men over the age of 70.[24, 26]  Although efforts have been made to better understand cancer 
care patterns in older adults and by race, independently, there is little literature examining the 
relationship between age and racial disparities in the management of aggressive cancers.  With a 
rapidly expanding population of minority older adults, it is critically important to understand this 
relationship. 
Lastly, prior studies have not examined the relationship between race and insurance 
status. With the implementation of the Affordable Care Act (ACA) and ongoing expansion of 
health insurance coverage, it is critically important to understand the influence that health 
insurance may have on racial treatment patterns in cancer care.[30, 31] 
In sum, prior studies that have examined prostate cancer outcome by race and other 
sociodemographics are either outdated and/or severely limited by the lack of details with regards 
to outcome by NCCN risk group and an updated effort with a contemporary cohort from a 
national database that more comprehensively captures treatment patterns and cancer outcome is 
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urgently needed to guide future interventions that seek to reduce racial disparities particularly 
among African American men in prostate cancer.  Herein, we used the Surveillance, 
Epidemiology, and End Results (SEER) database to determine the contemporary impact of race 
on the of receipt of treatment with curative intent among patients with intermediate to high-risk 
prostate cancer and whether any disparities in management patterns changed with NCCN risk 
group and/or over time, across age groups, or by insurance status. Based on a growing body of 
literature which has demonstrated poorer healthcare outcome among minority and disadvantaged 
populations, we hypothesize that African American men with prostate cancer will receive worse 
care and suffer higher rates of cancer death when compared to non-minority white patients with 
prostate cancer.  This study should guide future interventions which seek to reduce disparities in 
prostate cancer outcome.  
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Methods 
Patient Population and Study Design 
The Surveillance, Epidemiology and End Results Program (SEER) program, sponsored 
by the National Cancer Institute, collects and publishes cancer incidence, survival, and treatment 
data from population based cancer registries; the program captures approximately 97% of 
incident cancers and the 17 tumor registries encompasses about 26% of the US population.[32]   
The SEER program was used to identify 128,189 (107,869 white; 20,320 African 
American) men with localized intermediate to high-risk prostate cancer, defined by prostate-
specific antigen (PSA) > 10 or Gleason score >7 or stage cT2b or higher,[3] diagnosed from 
2004 – 2010, as previously described.[33]  Gleason scores, as provided by the SEER program, 
represent the highest Gleason score identified at surgery (or at biopsy for non-surgically 
managed patients).  Stage was determined using the AJCC 6th edition as provided by the SEER 
program.[32]  The inclusion period was limited to 2004 – 2010, as 2004 represents the year that 
several of the covariates included in our multivariable analyses were introduced to SEER and 
2010 represents the most recent year for which full information was available at the time of this 
study.  
Initial management was defined as curative-intent treatment versus non-curative 
treatment.  Curative-intent treatment was classified in accordance with the NCCN guidelines and 
included radical prostatectomy, external beam radiation therapy, brachytherapy, or any 
combination thereof.[3]  SEER also provides information on patient refusal of recommended 
definitive surgery or radiation.  Therefore, refusal of definitive treatment was classified as patient 
refusal of either surgery or radiation.  
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Race was classified as white and African American, as designated by the SEER 
program.[32] Income (computed as median household income) and educational status (computed 
as the percentage of residents >25 years of age with at least a high school education) were 
determined at the county level by linking to the 2000 United States Census; population means for 
each race were determined in order to provide the average county-level socioeconomic 
demographics for each race.[34] Residence type was also determined at the county level by 
linking to the 2003 United States Department of Agriculture rural-urban continuum codes.[35] 
We analyzed insurance coverage as a dichotomous variable given that SEER does not provide 
information on the specific type of insurance coverage that patients have. Specifically, a patient 
was considered “insured” if he was classified by SEER as “insured,” “insured/no specifics,” or 
“any Medicaid,” and patients were considered “uninsured” if he was classified as such.  
 
Statistical Analysis 
The primary outcome of this study was the use of curative-intent treatment for 
intermediate to high-risk prostate cancer diagnosed from 2004 – 2010.  Baseline clinical and 
demographic characteristics were compared using the t test and χ2 test, as appropriate.  
Multivariable logistic regression analyses were used to determine the association between race 
and the use of curative-intent treatment using 3 models: model 1 was adjusted for age; model 2 
was adjusted for age and prostate cancer-specific factors (cancer stage, Gleason score, and PSA); 
model 3 was adjusted for age, clinical factors, and other sociodemographics (marital status, 
income, education, and residence).[33]  Men were only included (N = 116,084; White 84.0%, 
African American 16.0%) in analyses if they had data on the aforementioned covariates.  These 
analyses were done for the entire cohort and also for men with intermediate-risk disease (PSA 10 
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– 20 or Gleason 7 or cT2b – T2c) and high-risk disease (PSA > 20 or Gleason 8 – 10 or cT3a – 
T4), separately.  Multivariable sensitivity analyses including insurance status (only available 
from 2007 – 2010) and cause of other death (non-prostate mortality) within 5 years of follow-up 
as a proxy for comorbidity were repeated for men with high-risk disease.  Also, multivariable 
logistic regression was used to determine whether there was an association between race and the 
rate at which curative-intent treatment was recommended but refused among men that did not 
undergo definitive therapy. 
Next, management type (defined above under “Patient Population and Study Design”) 
was analyzed stratified by race and age group (age < 70 vs age > 70) among men with high risk 
prostate cancer, with χ2 pairwise comparison tests made across each race and age group, as 
previously described.[36]  After adjusting for sociodemographics (age group, race, residence 
[urban versus rural], marital status, income, education) and prostate cancer-specific prognostic 
factors (PSA, Gleason score, and stage), multivariable logistic regression was used to determine 
whether there was an interaction between age (age < 70 vs age > 70) and race with respect to the 
use of definitive treatment among men with high risk prostate cancer with data on the 
aforementioned variables (N=58,874) via multiplicative multivariate logistic regression analysis.  
Furthermore, multivariable sensitivity analysis was done including other cause mortality (non-
PCSM) within 5 years of follow-up as a proxy for comorbidity. After adjusting for the previously 
listed covariates in addition to receipt of definitive therapy, Fine and Gray’s multivariable 
competing-risks regression was used to assess the secondary endpoints of the association of race 
on prostate cancer-specific mortality (PCSM) and also on other cause (non-PCSM) mortality (as 
a proxy for comorbidity).[37] 
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We then analyzed management type (defined above under “Patient Population and Study 
Design”) stratified by race and insurance status among men with high risk prostate cancer, with 
χ2 pairwise comparison tests made to compare across stratified groups, as previously 
described.[38]  After adjusting for demographic factors (age, race, insurance status, marital 
status, residence [urban vs rural], income, education, Gleason score, and cancer stage), 
multivariable logistic regression was used to determine whether there was a statistical interaction 
between insurance status and race with respect to the use of definitive treatment.  Since more 
than 1/3 of the uninsured patients were missing information on either PSA, Gleason score, or 
stage (a limitation inherent to SEER),[39] in order to not lose a disproportionately large 
proportion of uninsured patients from the multivariable analyses examining the influence of 
insurance status on disparities in prostate cancer outcome, we were only able to control for 
Gleason score and stage, since PSA was the most common missing variable among the uninsured 
(N = 64,277; including men with missing PSA values).  Sensitivity logistic regression analyses 
were used to determine whether any observed interaction remained significant by insurance type 
(Medicaid vs uninsured and privately insured [no specifics] vs uninsured). Furthermore, Fine and 
Gray’s multivariable competing-risks regression (adjusting for the aforementioned covariates in 
addition to receipt of definitive therapy) was used to assess the association of other cause (non-
prostate cancer-specific) mortality as a proxy for comorbidity among uninsured men with at least 
3 years of follow-up, given the lack of comorbidity information in SEER.[37]   
Lastly, after adjusting for sociodemographics, prostate cancer prognostic factors, and 
initial management (receipt of curative-intent treatment vs not), Fine and Gray’s multivariable 
competing-risks regression was used to assess the impact of race on prostate-cancer specific 
mortality (PCSM) as a secondary outcome measure.[37]  Cumulative incidences of PCSM 
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stratified by race were generated from the competing-risks regression model and displayed 
graphically.[40] Point estimates and associated confidence intervals (CI) were generated and 
compared using Gray’s k-mean P value.  Furthermore, competing-risks regression was used to 
assess the impact of race on other cause (non-prostate cancer) mortality as a proxy for 
comorbidity. 
All P values were two sided. The threshold of 0.05 was used to determine statistical 
significance.  Statistical analyses were performed using R version 2.12.0 software (R Foundation 
for Statistical Computing, Vienna, Austria) for calculations relating to Gray’s k-mean P value 
and STATA 13.1 (StataCorp, College Station, TX) for all remaining analyses.  This study was 
approved by the institutional review board; a waiver for informed consent was obtained. 
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Results 
Patient Characteristics 
Baseline patient clinical and demographic characteristics are shown in Table 1.[33]  
Clinically small, but significant differences were noted for age, income, education, marital status, 
residence (urban vs rural), PSA, Gleason, stage, and NCCN risk category (intermediate vs high) 
when comparing African American and white patients. Notably, African American patients were 
more likely to be uninsured (3.8% vs 1.4%, P < 0.001), present with a PSA greater than 
20ng/mL (24.6% vs 15.7%, P < 0.001) and high-risk disease (52.4% vs 48.7%, P < 0.001) and 
white men were more likely to present with cT3 – T4 disease (20.9% vs 16.3%, P < 0.001) when 
the two groups were compared.[33, 38] 
 
Prostate-Cancer Specific Mortality 
After a median follow-up of 39 months, cumulative incidence estimates of PCSM were 
significantly higher for African American men compared to white men among patients with 
intermediate to high-risk disease, with 5-year PCSM rates of 4.5% (95% CI 4.1 – 4.9%) for 
African American men and 3.4% (95% CI 3.3 – 3.6%) for white men (P < 0.001, Figure 1).[33]  
Furthermore, multivariable competing-risks regression analysis revealed an increased risk for 
PCSM among African American men compared to white men, with an Adjusted Hazard Ratio 
[AHR] of 1.12 (95% CI 1.01 – 1.25; P = 0.03), respectively.   
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Treatment Patterns 
The raw unadjusted rates of initial management type stratified by race are provided for 
the entire cohort in Table 1. After adjusting for age, known prostate cancer prognostic factors , 
and sociodemographic factors on multivariable analysis, African American patients were 
significantly less likely to receive curative-intent treatment (Table 2) when compared to white 
men among patients with intermediate to high-risk prostate cancer (Adjusted Odds Ratio [AOR] 
0.82; 95% CI 0.79 – 0.86; P < 0.001).[33]  There was a significant interaction between race and 
risk group (Pinteraction < 0.001) such that racial disparities in the receipt of treatment between 
African American and white men were significantly higher in high-risk disease (Adjusted OR 
0.60; 95% CI 0.56 – 0.64; P < 0.001) than intermediate-risk disease (Adjusted OR 0.92; 95% CI 
0.88 – 0.97; P = 0.04). 
When analyzed on a year-by-year basis from 2004 – 2010, African American men were 
consistently less likely to receive curative treatment when compared to white men among 
patients with high-risk disease (P < 0.001 for each year, from 2004 – 2010).  As displayed 
graphically in Figure 2, these disparities did not appear to improve over time (Pinteraction 2010 vs. 
2004 = 0.490).[33]   
Of note, among men with high-risk disease who did not receive definitive therapy, there 
was no difference in the adjusted odds of refusing recommended curative-intent treatment 
between African American and white patients on multivariable analysis (Adjusted OR 1.04; 95% 
CI 0.93 – 1.17; P = 0.45). 
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Treatment Patterns Stratified by Race and Age Group 
Unadjusted absolute management rates stratified by race (African American vs white) 
and age group (age < 70 vs age > 70) as analyzed by univariable analysis are displayed in Table 
3.[36]  Of note, African American men age 70 and above had the lowest rate of definitive 
therapy (52.0%) among men with high-risk prostate cancer.  AA men under the age of 70 were 
more likely to receive definitive therapy when compared to African American men age 70 and 
over (81.7% vs 52.0%; P < 0.001).  Similarly, white men age 70 and above were less likely to 
receive definitive therapy when compared to white men under the age of 70 (64.8% vs 91.1%; P 
< 0.001), however the absolute rate difference was not as pronounced as among the African 
American men detailed above.  Furthermore, among men age 70 and over, African American 
men were significantly less likely to receive definitive treatment when compared to white men 
(52.0% vs 64.8%; P < 0.001). 
There was a significant interaction between age group (age < 70 vs age > 70) and race 
(Pinteraction = 0.01) such that the adjusted odds of receiving definitive treatment for African 
American vs. white was 0.67 (95% CI 0.62 – 0.73; P < 0.001) among men younger than 70, but 
among men age 70 and older, the adjusted odds was 0.60 (95% CI 0.55 – 0.66; P < 0.001), 
suggesting an increased racial gap in the delivery of definitive treatment between African 
American and white patients among men age 70 and older (Table 4).[36]  Furthermore, in a 
sensitivity analysis we found that even after adjusting for non-PCSM mortality within 5 years (as 
a proxy for baseline comorbidity), the interaction between race and age remained significant 
(Pinteraction = 0.01) and the disparity in the receipt of definitive treatment remained higher among 
men age > 70 (AOR 0.61 among men 70 and older vs 0.68 among men age < 70; Table 5).[36] 
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Association of Race on PCSM and Other Cause Mortality among Men Age > 70 
After a median follow-up of 35 months, cumulative incidence estimates of PCSM were 
significantly higher among African American men age > 70 with high-risk disease when 
compared to white men, with 5-year PCSM rates of 15.8 % (95% CI 14.5 – 17.2%) and 12.5% 
(95% CI 12.2 – 13.2%), respectively (P < 0.001).  Furthermore, African American men age > 70 
with high-risk prostate cancer had a higher risk of PCSM compared to white men on 
multivariable analysis (AHR 1.20; 95% CI 1.02 – 1.38; P = 0.02).  However, there was no 
difference in other cause (non-PCSM) mortality between African American and white patients 
age > 70 (AHR 0.99; 95% CI 0.92 – 1.08; P = 0.91), suggesting no underlying difference in 
comorbidity that might have explained some of the disparity in the receipt of definitive therapy. 
 
Treatment Patterns Stratified by Race and Insurance 
Treatment patterns stratified by race and insurance status among men with high-risk 
prostate cancer are shown in Table 6.[38]  Uninsured African American men had the highest rate 
(27.8%) of not receiving definitive treatment among men with high-risk prostate cancer.  Insured 
African American men were more likely to undergo definitive therapy (84.5% vs 72.2%; P < 
0.001) when compared to uninsured African American men.  Similarly, white insured men were 
more likely to receive definitive therapy when compared to uninsured white men, although the 
difference (89.4% vs 84.3%, P < 0.001) was not as pronounced as for African American men 
with and without insurance, as detailed above.   
On logistic regression analysis, insured men with high risk prostate cancer were 
significantly more likely to receive definitive treatment when compared to uninsured men on 
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both univariable (OR 1.91; 95% CI 1.65 – 2.22; P < 0.001) and multivariable analysis (AOR 
1.79; 95% CI 1.50 – 2.14; P < 0.001).  A significant interaction between race and insurance 
status was found (Pinteraction = 0.01) such that insurance coverage was associated with a reduction 
in racial disparity between African American and white patients with regards to receipt of 
definitive therapy.  The unadjusted OR for definitive treatment for African American vs. white 
was 0.49 (95% 0.36 – 0.65; P < 0.001) among uninsured men, while the OR was 0.65 (95% CI 
0.61 – 0.69; P < 0.001) among insured men.  Furthermore, after adjustment for 
sociodemographics and cancer-specific factors, the AOR for definitive treatment for African 
American vs. white was 0.38 (95% CI 0.27 – 0.54; P < 0.001) among uninsured men, while the 
AOR was 0.62 (95% CI 0.57 – 0.66; P<0.001) among insured men. This significant interaction 
also suggests that the effect of insurance status on the receipt of definitive treatment differed by 
race.  Specifically, African American men appeared to have a larger increase in the receipt of 
definitive therapy when comparing uninsured to insured men (AOR 2.23; 95% CI 1.72 – 2.88; P 
<0.001) than white men did (AOR 1.47; 95% CI 1.15 – 1.89; P = 0.002; [Table 7]).[38]  
Furthermore, relative to white-insured men, African American men with insurance had more 
than twice the odds of receiving definitive treatment when compared to uninsured- African 
American men (Figure 3).  
Sensitivity analyses revealed that when stratifying results by insurance type (privately 
insured [no specifics] vs any Medicaid) that significant interactions remained between race and 
insurance status.  Specifically, there were significant interactions between race and private 
insurance/no specifics (P = 0.007) and also between race and Medicaid (P = 0.04) such that 
disparities in receipt of treatment were reduced from an AOR for definitive treatment for African 
American vs white men of 0.38 (95% CI 0.27 – 0.54; P < 0.001) among uninsured men to 0.65 
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(95% CI 0.60 – 0.70; P < 0.001) among privately insured men and to 0.58 (95% CI 0.46 – 0.73; 
P < 0.001) among men with Medicaid (Table 8).[38] 
 
Association of Race on Other Cause Mortality among Uninsured Men 
As a sensitivity analysis, we found that the risk of other cause (non-prostate cancer-
specific) mortality (analyzed as a proxy for comorbidity) among uninsured men with at least 3 
years of follow-up was not different between white and African American men (P = 0.54). This 
suggests that there is little difference in comorbidity status among the uninsured and a low 
likelihood that the increased disparity in receipt of definitive therapy among the uninsured was 
due to comorbidity differences. 
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Discussion 
In this study we found that, after adjusting for sociodemographics, known prostate cancer 
prognostic factors, and receipt of definitive treatment, African American men with intermediate 
to high-risk prostate cancer are at a 12% increased relative risk for PCSM when compared to 
white men; however, African American men receive curative-intent treatment 18% less often 
relative to white men. This disparity is even greater among high-risk patients, as African 
American men with high-risk disease were 40% less likely to receive curative treatment 
compared to white patients.  The magnitude of this disparity did not change over time.  
Furthermore, African American men with high-risk prostate have a 20% increased risk of PCSM 
when compared to white men among patients age > 70.  Despite this excess mortality, our results 
revealed greater disparities in the receipt of definitive therapy among men 70 and older. 
Specifically, we found that African American men with high-risk prostate cancer under the age 
of 70 were 33% less likely to receive definitive therapy when compared to white men from the 
same age group, while African American men age > 70 were 40% less likely to receive definitive 
therapy relative to white men age > 70.  Lastly, our results demonstrated that there was a 
significant interaction between race and insurance status on multivariable logistic regression 
analysis such that uninsured African American men were 62% relatively less likely to receive 
definitive treatment when compared to white uninsured men, while insured African American 
men were only 38% relatively less likely to receive definitive treatment when compared to 
insured white men.  Similarly, when examining the relationship between insurance status and 
race on the receipt of definitive treatment, the significant interaction suggested that African 
American men derived a larger benefit from being insured versus uninsured with respect to 
receipt of definitive therapy than white men did. 
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This study is novel and important because it identifies what are potentially immediately 
actionable contributors to excess prostate cancer mortality in African American men. Our study 
in a large national contemporary cohort comprehensively reports on racial treatment disparities 
as a highly problematic issue that has been persistent with time, that is alarmingly worse among 
men with high-risk disease who need treatment most, that is worse among older men, and that is 
improved by being insured and having greater access to care.  Furthermore, our study reports on 
worse prostate cancer-specific mortality among African American men that persists when 
controlling for potentially confounding sociodemographic variables. The underlying reasons for 
these racial disparities must be carefully studied and these findings could guide policy level 
intervention, as they identify potentially correctable contributors to excess prostate cancer 
mortality among African American patients.  
Our findings have important implications for racial treatment patterns in a new era 
defined by healthcare coverage expansion and the implementation of the Affordable Care Act.[1, 
31]  Our results suggest that insurance coverage may help reduce racial disparities in treatment 
patterns for aggressive cancers, likely by increasing access to care.  Based on these results, it 
could be postulated that with the expansion of health care coverage, one might expect greater 
access to care and a reduction in racial disparities in cancer-care patterns.  This would be 
particularly beneficial for African American men with high-risk prostate cancer who die from 
their cancer more frequently than white men and who experience a longer time to diagnosis and 
are less likely to receive definitive treatment even among patients with similar disease 
characteristics.[1, 20, 41]  Of note, addressing socioeconomic and racial disparities was one of 
the major aims of the ACA.[30, 31]  Nevertheless, it may be premature to directly link the results 
of this study to the ACA. 
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There is a paucity of literature examining the interaction between race and insurance and 
its association with cancer care patterns.  Previous studies focusing on insurance status in 
healthcare have indicated that being insured is associated with increased access to care and 
decreased morbidity and mortality in the management of patients (including those undergoing 
radical prostatectomy).[42-45]  Furthermore, it has been suggested that African American men 
and uninsured patients are less likely to have access to high-volume urologic surgeons and 
hospitals with access to robotic surgery.[46] However, there is literature to suggest that neither 
African American race nor insurance status are associated with the odds of receiving guideline-
concordant care.[21]  As pointed out by the authors of the study, the results were based on a 
small cohort (N = 777) of patients from North Carolina that may not be generalizable to the 
broader U.S. population and the analyses examining insurance status lacked precision due to the 
small number of uninsured patients (N=63).[21]  Nevertheless, this study by Ellis and colleagues 
represents a paradigm shift in the method by which disparities in prostate cancer should be 
studied and certainly guided the methods and design of this study; namely, disparities should be 
studied within, not across, NCCN risk groups.  Still, studies have not specifically examined the 
interaction between race and insurance status and it is difficult to determine how insurance 
coverage might influence racial disparities in cancer care patterns based on prior literature. 
Furthermore, our findings also have important implications for racial cancer care patterns 
in an aging population that is becoming more racially and ethnically diverse and that will 
continue to be impacted by a greater burden of prostate cancer among older adults. [1, 24, 47] 
Among men ages 60 – 79, the leading cause of death in the United States is cancer, with prostate 
cancer being the second leading cause of cancer death.[1]  The number of men age 65 and above 
in America increased by over 20 million from 2000 to 2010 and is expected to increase by 
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another 25 million over the next decade, with the population of older adults from minority 
groups expected to grow by nearly 25%.[47]  Given an increasing population of older adults 
(especially from minority groups) and increasing life expectancy in the United States, one can 
expect a greater number of older minority men to be diagnosed with prostate cancer in the near 
future.[1, 47]  Furthermore, with the new U.S. Preventive Services Task Force (USPSTF) 
recommendations against prostate-specific antigen (PSA) screening, there will likely be 
migration toward higher stage and grade among men with newly diagnosed prostate cancer.[48, 
49]  Based on our results, it can be postulated that without immediate intervention, one could 
expect an increase in racial disparities in the delivery of definitive treatment for high-risk 
prostate cancer in an aging population.  This would be particularly detrimental to African 
American men with aggressive prostate cancer who die from their cancer at higher rates than any 
other population and for whom potentially curative treatment is particularly important.   
The causes of excess prostate-cancer mortality among African American men are likely 
multifactorial.  African American men may have a biologic predisposition for aggressive disease, 
have poorer access to care, experience treatment delays, and/or receive care from lower volume 
and quality centers, all of which could lead to worse survival after a median follow-up of only 39 
months.  Unfortunately, SEER does not provide information on these potential factors of excess 
mortality and so we were unable to determine their impact on mortality. Although it is difficult 
to determine the underlying reasons for increased racial disparities in the treatment of men with 
prostate cancer, most of the literature has focused on patient preference, mistrust, socioeconomic 
status, provider and system level factors, and comorbidities as potential drivers of disparity.  [14, 
18, 19, 22, 41, 50-54]   
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To address some of these previously postulated hypotheses of drivers of prostate cancer 
disparities, we completed several sensitivity analyses.  First, although there is some evidence 
from the lung cancer literature that African American adults are more likely to refuse 
recommended treatment,[55] there was no difference in the rate at which treatment 
recommended by a provider was refused by African American vs. white patients with high-risk 
disease (OR 1.04; P = 0.45).  Nevertheless, mistrust by African American patients has been 
observed previously among men with prostate cancer,[51] and it is difficult to rule out the 
possibility that subtle mistrust of the healthcare system led to less definitive treatment.  Second, 
although lack of insurance can be a barrier to receiving adequate care, and insurance was a 
significant driver of treatment in our study, we found that racial disparities in the receipt of 
definitive treatment remained significant even after adjusting for insurance status (Table 2).  
Third, it is conceivable that African American men had higher baseline comorbidity and so the 
disparity in treatment may not have been entirely inappropriate, but we found that even after 
adjusting for non-prostate mortality within 5 years of follow-up (as a proxy for comorbidity), the 
disparities remained significant (Table 2).  Provider level factors may also contribute to the 
observed race-risk interaction and disparity.  For example, if providers over-estimate the 
comorbidity burden of African American patients, this may lead them to recommend definitive 
treatment less frequently.  Alternatively, providers may not be sufficiently communicating to 
African American men with higher risk disease that their disease is significantly more lethal and 
needs to be treated more urgently than if they had intermediate-risk disease.  This possibility is 
suggested by the fact that among white patients, the treatment rate increases by 14.1% as patients 
move from intermediate to high risk disease, but among African American patients, the treatment 
rate increases by only 7.3% between intermediate and high risk disease.  Lastly, it has been 
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shown that physicians tend to underestimate the life expectancy of patients with high-risk 
prostate cancer,[52] and it could be the case that this underestimation is larger among African 
American men leading to more disparate patterns of care among older men, although there is no 
variable to test that assumption in SEER. 
We also completed sensitivity analyses to further examine some of the aforementioned 
hypotheses for underlying reasons for increased disparities in the treatment of older adults with 
prostate cancer.  First, it is possible that African American men may have had higher 
comorbidity than white men among patients 70 and older and the excess disparity in receipt of 
treatment among men age > 70 may not have been entirely inappropriate.  However, we found 
that among men age > 70 with high-risk prostate cancer, African American men had no 
difference in the risk of other cause mortality when compared to white men on multivariable 
analyses (Adjusted HR 0.99; P = 0.91) .  Furthermore, we found that even after adjusting for 
non-PCSM within 5 years (as a proxy for baseline comorbidity), although the comorbidity proxy 
was a significant driver against the receipt of definitive therapy, the interaction between race and 
age remained significant (Pinteraction = 0.01) and the disparity in the receipt of definitive treatment 
remained higher among men age > 70 (Table 4).  
To put our study into historical context, Underwood et al found in a SEER cohort from 
1992 – 1999, that African American men with moderately differentiated prostate cancer 
(Gleason 5 – 7) and poorly/undifferentiated prostate cancer (Gleason 8 – 10) were 46% and 51% 
less likely to undergo definitive treatment when compared to white patients, respectively,[14]  
and other more recent studies have also noted racial disparities in the use of potentially curative 
treatment among men with prostate cancer.[21, 22, 56]  However, results have been conflicting 
as to the impact of risk-group on racial disparities.  For example, although these disparities in 
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management appear in some studies to be larger among men who might benefit more from 
treatment,[22, 56] Ellis and colleagues did not find differences in racial disparities by NCCN risk 
groups when looking at a North Carolina state database.[21]  Our study is unique in that it 
elucidates disparities in cancer-specific outcomes and patterns of oncologic care for prostate 
cancer across NCCN risk groups, and across age groups and insurance status in a large national 
population. In light of these results, efforts should be made to ensure that all men with aggressive 
disease receive curative treatment at similar rates regardless of sociodemographics.  Addressing 
the underlying barriers to receipt of treatment could potentially improve outcomes for African 
American men.[21, 57, 58]  Although there is little evidence of interventions that reduce 
disparities in patterns of cancer care and outcomes, the Centers for Disease Control and 
Prevention (CDC) has partnered with public health agencies, providers, and communities to 
facilitate a national effort aimed at reducing disparities in cancer.   
Although more research is needed to further elucidate the underlying reasons for 
disparities in cancer-outcomes, particularly for African American men with prostate cancer, our 
results demonstrate an actionable item that can be implemented in the imminent future to reduce 
these disparities.  Specifically, expanding health care insurance (including Medicaid) may lead to 
more equal treatment patterns across races for aggressive cancers.  Additionally, shared decision 
making as encouraged by the Affordable Care Act could also lead to more accurate risk 
perceptions and a greater likelihood of receiving care aligned with patient values.[30, 58]  These 
could be some of the major benefits of expansion of health care through the Affordable Care 
Act.[30]  Notably, a similar reduction in racial disparities in treatment patterns for receipt of 
minimally invasive surgery (laparoscopic cholecystectomy and appendectomies) was observed 
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after the 2006 Massachusetts insurance expansion by Loehrer et al, however this study did not 
examine patterns of cancer-care.[45] 
Nevertheless, even among insured men, our results display that disparities in the receipt 
of definitive treatment for high-risk cancer still exist and closing the gap in disparate treatment 
patterns will likely not be done by expanding insurance coverage alone.  Well-defined treatment 
options for high-risk prostate cancer are likely being underused for African American men even 
when adjusting for health insurance coverage, as demonstrated by the results in our study.  
Specifically, efforts in health care should be made to treat African American men with high-risk 
cancers in a culturally competent manner at similar rates as white men, across insurance status 
and other socioeconomic determinants.   
Ideally, the goal of reducing disparities in the receipt of potentially curative treatment is 
to achieve equally high rates of treatment when it is warranted among all groups of patients, 
which will in turn close racial disparities.  Specifically, following the well-delineated NCCN 
guidelines (which ubiquitously recommend definitive therapy for men with high-risk disease, 
without specifying age or life expectancy cutoffs for observation) in a culturally competent and 
compassionate manner is critically important to closing disparity gaps.  To reduce disparate 
outcomes in aggressive cancers it is clear that there will need to be equal access to cancer 
screening, interventions at the community level to educate populations about the risks of 
aggressive cancers, clinical trials which include adequate numbers of minority participants, and 
prospective research of interventions that can help determine the most efficacious approach to 
alleviating cancer disparities.[55, 57, 59, 60]  These interventions will take time before targets 
are achieved.  Meanwhile, one method of achieving more immediate reductions in disparities in 
cancer outcomes may be done by setting race-neutral treatment of aggressive disease as a quality 
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metric that an institution must achieve to reach a certain quality status.  Although there are no 
national benchmarks for prostate cancer care, an 80% benchmark for adherence to guideline-
concordant care has been proposed by Ellis and Colleagues.[21]  Several payers are now 
expecting providers to adhere to treatment pathways, and there has been a gradual introduction 
of pathway databases where the type of treatment received by each patient can be tracked on a 
provider level to determine how often the provider deviated from the standard pathway.  
Ultimately, by measuring adherence to pathways for high-risk prostate cancer, we may begin to 
see these racial disparities narrow. Similarly, given that it has been suggested that African 
American men have less access to high quality care and high volume centers, an effort should be 
made to ensure that African American men have equal access to affordable high volume and 
quality health centers.[46]   
There are several potential limitations to our study.  The SEER database does not have 
information on comorbidity, and so it is conceivable that the decreased rate of treatment among 
African American patients is not entirely inappropriate.  We completed a sensitivity analysis and 
found that African American men had a higher risk of other-cause mortality (AHR 1.33; 95% CI 
1.23 – 1.43; P < 0.001), suggesting that they may have higher baseline comorbidity in this 
cohort.  However, as mentioned above, when we adjusted for insurance status and other-cause 
mortality as a proxy for comorbidity in the logistic regression model for receipt of curative-intent 
treatment, the odds ratio for treatment among African American men only increased from 0.60 to 
0.63 (P < 0.001) (Table 2), suggesting any comorbidity likely accounts for only a small 
component of the disparity in treatment.  We also found that the risk of other cause (non-prostate 
cancer-specific) mortality (analyzed as a proxy for comorbidity) among uninsured men with at 
least 3 years of follow-up was not different between white and African American men (P = 
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0.54), suggesting little difference in comorbidity status among the uninsured. Additionally we 
found that the risk of other cause of death (non-PCSM) was not different (HR 0.99; P = 0.91) 
between white and African American men age > 70, suggesting little to no difference in 
comorbidities between the two groups.  Furthermore, when adjusting for non-PCSM mortality 
(as a proxy for comorbidity) via multivariable sensitivity analysis, the race-age interaction 
remained significant with greater disparities in treatment among men 70 and older (Table 5).  
Although this comorbidity proxy is based on the best information we have to approximate 
comorbidity information in SEER, it likely still does not completely capture comorbidity status 
and so it still cannot be ruled out that African American, uninsured, or older men suffered from 
higher rates of comorbidity in our cohort.  Second, our statistical adjustments for income, 
education, and residence (urban vs rural) were linked at the county, not individual, level as 
provided by the state and county codes in SEER.  Third, in regards to secondary endpoints, the 
median follow-up of this study was only 39 months; nevertheless, significant differences in 
PCSM were already observed between white and African American men.  Longer follow-up is 
required to determine whether the magnitude of the observed differences in PCSM will increase 
with time.  Fourth, we were not able examine whether racial disparities in health care prior to 
diagnosis of prostate cancer, such as access to prostate cancer screening, may have impacted 
survival.  Previous studies have shown lower rates of undergoing proper screening and staging 
among African American men.[53]  Fifth, SEER replaces the biopsy Gleason score with the 
prostatectomy Gleason score for surgically managed patients, thus these results may have been 
underestimates of the true magnitude of the difference in PCSM between African American and 
white men given that African American men are more likely to get upgraded at 
prostatectomy;[17] thus, for example, the patient with Gleason 6 at biopsy but Gleason 7 at 
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radical prostatectomy patient (who is more likely to have better outcomes) is more likely to be 
African American than white.  Nevertheless, our findings still revealed that African American 
men have worse PCSM outcomes when compared to white patients.  Sixth, SEER does not 
provide information on quality metrics (including androgen deprivation therapy, provider 
volume, and complications) of the centers at which patients are receiving care or time from 
diagnosis to receipt of treatment.  Therefore, as has previously been shown, African American 
men may be receiving their care at lower volume centers with poorer quality metrics and may be 
experiencing delays in receipt of treatment which may be contributing to some of the excess 
PCSM observed in our study.[41] Seventh, it is possible that SEER does not capture all episodes 
of curative treatment.  Specifically, it is possible that African American men may have 
experienced more delays from diagnosis to treatment, and some curative therapies therefore may 
not have been captured by the registries. Future SEER studies should aim to determine the extent 
to which this limitation exists.  Eighth, SEER does not provide information about insurance 
coverage periods or the details of the insurance plans that patients have and so we analyzed 
insurance coverage as a binary variable. Nevertheless, on sensitivity analyses, the associations 
and interactions observed in this study remained when stratifying by insurance type as broadly 
provided by SEER (Medicaid vs uninsured or private insurance [no specifics] vs uninsured; 
Table 8).  Ninth, there was a small number of uninsured patients in our cohort (N = 1,136).  
Although this study is limited by the number of uninsured patients that are included, previous 
studies focusing on the impact of both race and insurance status on the receipt of definitive 
therapy for prostate cancer had fewer than 65 uninsured patients.[21]  Tenth, over 35% of the 
uninsured patients were missing information on either PSA, Gleason score, or stage; although 
this is a limitation inherent to SEER, in order to not lose a large proportion of uninsured patients 
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from our multivariable analyses, we were only able to control for Gleason score and stage, since 
PSA was the most common missing variable among the uninsured.   
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Conclusion, Summary, and Future Direction 
Despite the potential limitations of our SEER-study, our findings in a large national 
contemporary cohort indicate that African American men with intermediate to high-risk prostate 
cancer are at higher risk for PCSM and undertreatment when compared to white patients 
independent of known prostate cancer prognostic factors and sociodemographic factors.  This 
disparity in receipt of definitive treatment is significantly greater among men with high-risk 
disease and among men age >70, and is not improving over time.  Having health insurance was 
associated with a reduction in this racial treatment disparity. This study is important in that it 
highlights previously understudied and undervalued significant relationships between race and 
NCCN risk group, race and age, and also between race and insurance status.  With the ongoing 
expansion of healthcare and an aging population and a greater burden of prostate cancer in older 
minority adults on the horizon, these results both suggest that expansion of health insurance 
coverage may help reduce racial disparities in the management of aggressive prostate cancer and 
highlight the need for urgent intervention that should be made to ensure that potentially curative 
treatment is delivered to all patients regardless of race, age or background when warranted in 
order to prevent increasing disparities in cancer care. 
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Table 1.  Baseline clinical and demographic characteristics. Previously published. [33] 
Characteristic  White (N = 
97,548) 
 
African 
American (N = 
18,536)  
P-value (AA 
vs White) 
Age, years, mean 
(SD) 
 66.4 (8.9) 63.6 (9.0) < 0.001 
Income, USD, mean 
(SD) a 
 47,000 
(12,000) 
44,000 (11,000) < 0.001 
Percent that 
completed high 
school, mean (SD) a 
  80.1 (7.6) 78.0 (7.0) <0.001 
Residence, (%)†    <0.001 
 Rural 12.8 9.2  
 Urban 87.2 90.8  
Married, (%)    <0.001 
 No 21.9 40.0  
 Yes 78.1 60.0  
Insured, (%)    <0.001 
 No 1.3 3.8  
 Yes 98.7 96.2  
PSA, median (IQR)  6.3 (4.7 – 9.7) 7.1 (4.9 – 19.2) <0.001 
PSA    <0.001 
 < 10 ng/ml 75.9 66.4  
 10 – 20 ng/ml 8.4 9.0  
 > 20 ng/ml 15.7 24.6  
Gleason    0.04 
 Gleason < 7 74.3 73.5  
 Gleason 8 – 10  25.7 26.5  
Stage, (%)    <0.001 
 < T2c 79.1 83.7  
 T3a – T4 20.9 16.3  
NCCN Risk Category    <0.001 
 Intermediate 51.3 47.6  
 High 48.7 52.4  
Treatment Received    <0.001 
 Not Managed 
Curatively 
26.0 30.0  
 Radical 
Prostatectomy 
25.5 19.3  
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 Radiation 
(EBRT and/or 
Brachytherapy) 
45.1 48.1  
 Combination 
Therapy 
3.4 2.6  
a County-level data 
 
Abbreviations: AA = African American; EBRT = External Beam Radiation Therapy; N = 
Number; NCCN = National Comprehensive Cancer Network; SD = Standard Deviation; USD = 
United States Dollar 
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Table 2. Multivariable logistic regression analyses for odds of receiving curative-intent 
treatment (radical prostatectomy, external beam radiation therapy, brachytherapy, or any 
combination thereof) for men diagnosed with prostate cancer from 2004 – 2010, according to 
National Comprehensive Cancer Network risk stratification. (N = 116,084: White 84.0%, AA 
16%). (Pinteraction intermediate-risk vs. high-risk disease < 0.001).  Previously published. [33] 
Characteristic  Multivariable Analysis 
 
Adjusted OR for 
receipt of curative-
intent treatment 
(95% CI) 
P-value 
Intermediate to High-Risk Prostate Cancer 
(Entire Cohort, N = 116,084) 
  
Race (Model 1) a   < 0.001 
 White 1.0 (Ref)  
 African American 0.67 (0.65 – 0.70)  
Race (Model 2) b   < 0.001 
 White 1.0 (Ref)  
 African American 0.76 (0.74 – 0.79)  
Race (Model 3) c   < 0.001 
 White 1.0 (Ref)  
 African American 0.82 (0.79 – 0.86)  
Intermediate-Risk Prostate Cancer (N = 58,874)   
Race (Model 1) a   < 0.001 
 White 1.0 (Ref)  
 African American 0.86 (0.82 – 0.90)  
Race (Model 2) b   < 0.001 
 White 1.0 (Ref)  
 African American 0.88 (0.84 – 0.92)  
Race (Model 3) c   0.04 
 White 1.0 (Ref)  
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 African American 0.92 (0.88 – 0.97)  
High-Risk Prostate Cancer (N = 57,210)   
Race (Model 1) a   <0.001 
 White 1.0 (Ref)  
 African American 0.40 (0.38 – 0.43)  
Race (Model 2) b   <0.001 
 White 1.0 (Ref)  
 African American 0.54 (0.51 – 0.57)  
Race (Model 3) c   <0.001 
 White 1.0 (Ref)  
 African American 0.60 (0.56 – 0.64)  
Sensitivity Analysis for men with High-Risk 
Prostate Cancer (N = 32,662) d 
  
Race    <0.001 
 White 1.0 (Ref)  
 African American 0.63 (0.58 – 0.69)  
Insurance Status   < 0.001 
 Insured 1.0 (Ref)  
 Uninsured 0.39 (0.32 – 0.48)  
Comorbidity / Death due 
to other cause 
  < 0.001 
 No death due to 
other cause / No 
Comorbidity 
1.0 (Ref)  
 Death due to other 
cause / Comorbidity 
0.34 (0.29 – 0.40)  
a Adjusted for age. 
b Adjusted for age and cancer-specific factors (cancer stage, Gleason score, and PSA). 
c Adjusted for age, cancer-specific factors ( cancer stage, Gleason score, PSA), and 
sociodemographic factors (marital status, income, education, residence). 
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d Adjusted for age, cancer-specific factors ( cancer stage, Gleason score, PSA), and 
sociodemographic factors (marital status, income, education, residence), insurance status, and 
death due to other cause within 5 years of follow-up (as a proxy for comorbidity). 
 
Abbreviations: OR = Odds Ratio 
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Table 3. Proportion of men diagnosed with high-risk prostate cancer from 2004 – 2010 
(N=58,874) receiving definitive therapy stratified by race (African American vs white) and age 
group (age > 70 vs age < 70). Previously published. [36] 
Therapy %White 
Age > 70 (N 
=19,153) 
%White 
Age < 70 
(N =29,722) 
 
%African 
American 
Age > 70 
(N = 2,865) 
%African 
American 
Age < 70 
(N = 7,134) 
P-valuea 
Definitive 
Therapy 
64.8 91.1 52.0 81.7 P < 0.001 
No Definitive 
Therapy 
35.2 8.9 48.0 18.3 P < 0.001 
a P < 0.001 with all pairwise comparisons across each row 
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Table 4. Assessment of effect modification between age group (age > 70 vs age < 70) and race 
(AA vs white) for the outcome of receipt of definitive therapy. All men were diagnosed with 
high-risk prostate cancer from 2004 – 2010 (N=58,874). Previously published. [36] 
Characteristic  Multivariable Analysisb 
 
 
 Adjusted OR (95% CI)a  P-value 
Interaction for receipt of 
definitive therapy 
  0.01c 
Age Group    
Age < 70     
 Race   < 0.001 
  White 1.0 (ref)  
  AA 0.67 (0.62 – 0.73)  
Age > 70     
 Race   < 0.001 
  White 1.0 (ref)  
  AA 0.60 (0.55 – 0.66)  
a Adjusted OR comparing the rate of receipt of definitive treatment. 
b Multivariable analyses are adjusted for age group, income, education, residence, marital status, 
prostate-specific antigen (PSA), Gleason score, and cancer stage. 
c P value for interaction term tests whether there is a significant difference in the OR between 
white and African American patients. 
 
Abbreviations: AA = African American; OR = Odds Ratio 
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Table 5. Sensitivity analysis of interaction and effect modification between age group and race 
for the outcome of receipt of definitive therapy, including non-prostate mortality as a proxy for 
comorbidity. All men were diagnosed with high-risk prostate cancer from 2004 – 2010 
(N=58,874). Previously published. [36] 
Characteristic  Multivariable Analysisb 
 
 Adjusted OR 
(95% CI)a 
P-value 
Interaction for receipt of definitive 
therapy 
  0.01c 
Age Group    
Age < 70     
 Race   < 0.001 
  White 1.0 (ref)  
  AA 0.68 (0.63 – 
0.74) 
 
 Comorbidity / Non-
Prostate Mortality 
  < 0.001 
  No Comorbidity / Non-
Prostate Mortality 
1.0 (ref)  
  Comorbidity / Non-
Prostate Mortality 
0.38 (0.32 – 
0.45) 
 
Age > 70     
 Race   < 0.001 
  White 1.0 (ref)  
  AA 0.61 (0.56 – 
0.67) 
 
 Comorbidity / Non-
Prostate Mortality 
  < 0.001 
  No Comorbidity / Non-
Prostate Mortality 
1.0 (ref)  
  Comorbidity / Non-
Prostate Mortality 
0.44 (0.40 – 
0.49) 
 
a Adjusted OR comparing the rate of receipt of definitive treatment. 
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b Multivariable analysis is adjusted for age, income, education, residence, marital status, prostate-
specific antigen (PSA), Gleason score, and cancer stage. 
c P value for interaction term tests whether there is a significant difference in the OR between 
white and African American patients. 
 
Abbreviations: AA = African American; OR = Odds Ratio 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
49 
 
Table 6. Proportion of men diagnosed with high-risk prostate cancer receiving each therapy type 
stratified by race and insurance status (N = 64,277; including men with missing PSA values). 
Previously published. [38] 
Therapy %White 
Insured (N = 
53,338) 
%White 
Uninsured 
(N = 753) 
 
%African-
American 
Insured 
(N = 9,803) 
%African-
American 
Uninsured 
(N = 383) 
aP-value 
Non-Definitive 
Therapy 
10.6 15.7 15.5 27.8 <0.001 
Definitive Therapy 89.4 84.3 84.5 72.2 <0.001 
a P < 0.001 with all pairwise comparisons across each row 
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Table 7. Assessment of effect modification between insurance status and race for the outcome of 
employment of definitive therapy. All men were diagnosed with high-risk prostate cancer (N = 
64,277; including men with missing PSA values). Previously published. [38] 
Characteristic aMultivariable Analysis 
 
Adjusted OR (95% CI) P-value 
Interaction for employment of definitive 
therapyb 
 0.01b 
White Men   
 Uninsured Ref (1.0) 0.002 
 Insured 1.47 (1.15 – 1.89)  
African-American Men   
 Uninsured Ref (1.0) < 0.001 
 Insured 2.23 (1.72 – 2.88)  
a Multivariable analyses are adjusted for age, income, education, residence, cancer stage, and 
Gleason score. 
b P value for interaction term tests whether there is a significant difference in the OR between 
white and African-American patients. 
 
Abbreviations: OR = Odds Ratio 
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Table 8. Sensitivity analysis of effect modification between insurance status (by type: privately 
insured/no specifics vs uninsured and Medicaid vs uninsured) and race for the outcome of 
employment of definitive therapy. All men were diagnosed with high-risk prostate cancer (N = 
64,277; including men with missing PSA values). Previously published. [38] 
Characteristic aMultivariable Analysis 
 
Adjusted OR (95% 
CI) 
P-value 
Uninsured Patients   
Race    
 White Ref (1.0) < 0.001 
  African American 0.38 (0.27 – 0.54)  
Privately Insured (No Specifics) Patients   
Interaction for employment of definitive 
therapyb 
 0.007b 
Race    
 White Ref (1.0) < 0.001 
  African American 0.65 (0.60 – 0.70)  
Medicaid Patients   
Interaction for employment of definitive 
therapyc 
 0.04c 
Race    
 White Ref (1.0) < 0.001 
  African American 0.58 (0.46 – 0.73)  
a Multivariable analyses are adjusted for age, income, education, residence, cancer stage, and 
Gleason score. 
b,c Value for interaction term tests whether there is a significant difference in the OR between 
uninsured and privately insured (no specifics) patients [b] or between uninsured and Medicaid 
patients [c]. 
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Abbreviations: OR = Odds Ratio 
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Figure 1. Cumulative incidence of prostate cancer-specific mortality (PCSM) for men with 
intermediate to high-risk prostate cancer, by race (N = 116,084: White 84.0%, AA 16%; Gray’s 
k-mean P < 0.001). Previously published. [33] 
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Figure 2. Plot of adjusted odds ratios and 95% confidence intervals along with trend line for the 
association between race (African American versus White [Referent]) and receipt of curative-
intent treatment for men with high-risk prostate cancer (PSA > 20 or Gleason 8 – 10 or T3a – 
T4). Odds ratios are adjusted for age, marital status, income, education, residence, cancer stage, 
Gleason score, and PSA. (Pinteraction 2010 vs. 2004 = 0.490).  Previously published. [33] 
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Figure 3. Adjusted odds ratios and associated 95% confidence intervals for the receipt of 
definitive treatment after adjusting for sociodemographics and cancer-specific prognostic factors, 
using white insured patients as the referent group (AOR 1.0). Abbreviations: AOR = Adjusted 
Odds Ratio; AA = African American. Previously published. [38] 
 
 
 
